
Medicalgorithmics S.A.
Other research and experimental development on natural sciences and engineering
Overview
Medicalgorithmics is a Warsaw Stock Exchange-listed company developing technologies for cardiology. Its offering includes devices and platforms such as PocketECG, Kardiobeat.ai, AI & Software Platform, DeepRhythmAI (DRAI), DeepRhythm Platform (DRP), and Virtual Cardiac Stress Test (VCAST). The company also works in clinical trials, research and developments, and advanced diagnostics.
Financials
Revenue history (in m)
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 47 days late). All were audited by a statutory auditor.
- 202522/06/2026
- 202423/06/2025
- 202313/06/2024
- 202213/07/2023
- 202131/08/2022
- 202028/06/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Stock quotes
- Open
- PLN 21.90
- High
- PLN 22.00
- Low
- PLN 21.20
- Volume
- 12.84K
- Avg. vol.
- 40.58K
- Market cap
- PLN 212.99M
- P/E ratio
- –
- EPS
- -PLN 0.70
- Shares outstanding
- 9.95M
- 52-week
- PLN 20.20 – 23.45
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLMDCLG00015
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 2.93m | USD -1.35k | USD 35.93k |
| Q1 2026 | USD 2.76m | USD -100.76k | USD -580.23k |
| Q4 2025 | USD 2.52m | USD -88.90k | USD -235.31k |
| Q3 2025 | USD 1.81m | USD -846.31k | USD -1.02m |
Results for Q3 2026:Nov 26, 2026
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News
Medicalgorithmics advances AI research pipeline targeting automated diagnostics and population-scale cardiac prevention
Medicalgorithmics Advances AI Research Pipeline Targeting Automated Diagnostics and Population-Scale Cardiac Prevention
Biofund is proceeding with its plans to convert the loan granted to Medicalgorithmics. The General Meeting will make a key decision
Biofund is proceeding with its plans to convert the loan granted to Medicalgorithmics. The General Meeting will make a key decision
Medicalgorithmics is entering business talks with a global MedTech company listed on the NYSE with a multi-billion-dollar business
Medicalgorithmics is entering a business talks with a global MedTech company listed on the NYSE with a multi-billion-dollar business
Medicalgorithmics announces a technology partnership with Accyourate, an Italian wearable healthcare company
Medicalgorithmics a technology partnership with Accyourate, an Italian wearable healthcare company
Medicalgorithmics summarizes Q1 2025: 51% revenue growth, positive EBITDA and positive operating cash flow
Medicalgorithmics Summarizes the Q1 2025 51% revenue growth, positive EBITDA, and positive operating cash flow
Medicalgorithmics enters the field of cardiac surgery robotics
Medicalgorithmics is entering the field of cardiac surgery robotics
Industry
Websites
- medicalgorithmics.plMedicalgorithmics – najskuteczniejsze rozwiązania technologiczne w kardiologiiWordPress 7.1ElementorLinkedIn AdsGoogle AnalyticsGoogle Tag ManagerYoast SEOWWPMLLLiteSpeed
Public procurement
1 tender recorded as contractor, with a total value of $10,773.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Aug 26, 2025 | Equipping outpatient specialist care at SPZOZ w Działdowie with modern medical equipment and apparatus | $10,773$10,773 | Samodzielny Publiczny Zakład Opieki Zdrowotnej w Działdowie |
Medicalgorithmics has been a party to 1 case before the National Appeal Chamber (since 2019).
| Date | Subject of dispute | Outcome | Other party | |
|---|---|---|---|---|
| Sep 4, 2019 | Order | Authority accepted the complaints | Copernicus Podmiot Leczniczy sp. z o.o. |
Trademarks
The company currently holds no active trademarks with the Polish Patent Office. 2 marks have expired or were not registered. The first mark was filed in 2014.
| Mark | Number | Classes | Status | Protected until | |
|---|---|---|---|---|---|
| POCKET ECG | Z.432904 | 44 | Expired | – | |
| MEDICALgorithmics | Z.432903 | 10, 44 | Expired | – |
| Mark | Protected until | |
|---|---|---|
| POCKET ECG | – | |
| MEDICALgorithmics | – |
Job offers
The company has its own careers page: medicalgorithmics.pl/about/job-offers.
Authorized Representatives
Manner of representation
In the case of a multi-member management board, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.
Supervisory board
Beneficial owners
Medicalgorithmics is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Medicalgorithmics Polska sp. z o.o. | 81,037.28 USD | 100% |
Bank accounts
Registered as a VAT taxpayer on 2005-09-09.
58 1160 2202 0000 0001 4133 6132
55 1160 2202 0000 0002 6271 6845
86 1600 1462 1744 0482 6000 0002
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jun 26, 2026 | Commercial Companies Code notice |
Public aid
11 public aid cases recorded, with a total value of $4,383,519.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jul 21, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | PREZYDENT MIASTA GDAŃSK | |
| Dec 17, 2025 | Aid for research and development projects: experimental development | –– | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Dec 17, 2025 | Aid for research and development projects: experimental development | –– | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2026-01-01 | Quantifying atrial fibrillation burden to inform screening, treatment, and health policy | $0$0 | DA/JU/EUI - Decentralised Agencies, Joint Undertakings, EU institutions |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Genexo sp. z o.o. | $19,276,689.51 | genexo.pl | ||
| Egzotech sp. z o.o. | $7,802,789.60 | egzotech.com | ||
| Zakład Techniki Medycznej Tech-Med sp. z o.o. | $7,640,728.17 | technikawmedycynie.pl | ||
| Aspel S.A. | $6,189,656.66 | aspel.com.pl | ||
| Sidly sp. z o.o. | $4,977,649.42 | sidly.eu | ||
| Elmiko Biosignals sp. z o.o. | $4,001,404.53 | elmiko.pl | ||
| Emtel Śliwa sp. k. | $3,712,517.07 | emtel.com.pl | ||
| Horizon Business Hub sp. z o.o. | $2,729,615.25 | horizonhub.pl | ||
| Em-Med sp. z o.o. | $1,902,460.88 | emmed.pl | ||
| M4medical sp. z o.o. | $901,741.01 | m4medical.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-09-09 | Share capital increase (995,276.90 PLN → 1,045,338.90 PLN) | |
| 2022-11-29 | Share capital increase (497,638.50 PLN → 995,276.90 PLN) | |
| 2021-12-15 | Share capital increase (432,782.90 PLN → 497,638.50 PLN) | |
| 2020-04-06 | Share capital increase (360,652.60 PLN → 432,782.90 PLN) | |
| 2016-05-11 | Share capital increase (345,552.60 PLN → 360,652.60 PLN) |
FAQ
Last updated: 2026-09-09